A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Solid Tumors
Interventions
DRUG

VVD-130037

Oral tablets

DRUG

Docetaxel

IV infusion

DRUG

Paclitaxel

IV infusion

Trial Locations (25)

22031

RECRUITING

NEXT Virginia, Fairfax

32224

RECRUITING

Mayo Clinic Jacksonville, Jacksonville

33612

RECRUITING

Moffitt Cancer Center, Tampa

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

55905

RECRUITING

Mayo Clinic Rochester, Rochester

75039

RECRUITING

NEXT Dallas, Irving

77030

RECRUITING

MDACC, Houston

Unknown

NOT_YET_RECRUITING

National Cancer Center, Goyang

NOT_YET_RECRUITING

Gachon University Gil Medical Center, Incheon

NOT_YET_RECRUITING

Seoul National University; Bundang Hospital, Seongnam

NOT_YET_RECRUITING

Asan Medical Center, Seoul

NOT_YET_RECRUITING

Samsung Medical Center, Seoul

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

NOT_YET_RECRUITING

Severance Hospital; Yonsei University Health System, Seoul

NOT_YET_RECRUITING

The Catholic University of Korea, St. Vincent's Hospital, Suwon

RECRUITING

Hospital Vall d'Hebron, Barcelona

RECRUITING

START Barcelona Hospital HM Nou Delfos, Barcelona

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

NOT_YET_RECRUITING

Hospital Universitario Ramon y Cajal, Madrid

RECRUITING

NEXT Madrid, Madrid

RECRUITING

START Madrid CIOCC, Madrid

RECRUITING

Start Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid

NOT_YET_RECRUITING

Clinica Universitaria de Navarra, Pamplona

RECRUITING

Hospital Clinico Universitario de Valencia, Valencia

All Listed Sponsors
lead

Vividion Therapeutics, Inc.

INDUSTRY